The Mexico pharmaceutical market was valued at $21.48 billion in 2020. Mexico has a large and rising middle-class population, a favorable environment for private sector investment, a rise in demand for healthcare services, and relatively high drug prices. The growth of the Mexican pharmaceutical market can be attributed to the large and growing middle-class population, the favorable environment for private sector investment, a rise in demand for healthcare services and pharmaceutical products, and increased quality certifications.
Low-cost manufacturing of pharmaceuticals is attracting increasing foreign investment to Mexico. Many US manufacturing companies aiming to reduce dependence on China perceive nearshoring to Mexico or Canada as even more advantageous than reshoring to the US. Since 2020, COVID-19-related supply chain disruptions have caused many US companies to take steps to bring some of their manufacturing closer to home.
Mexico pharmaceutical market overview
For more insights on this report, download a free report sample
What are the key market trends and drivers in the Mexico pharma industry?
The Mexico pharma industry grew significantly with the repeal of the “derecho de planta” law in 2010, part of the country’s economic liberalization under the conservative PAN party, which required all companies selling pharmaceuticals in Mexico to have a manufacturing facility in the country. Although the rising number of middle-class people in Mexico will fuel growing domestic pharma production, there will be limits to the fast pharma growth. Mexico is also heavily dependent on US markets, as the US is one of its best-trading partners.
There has been a trend toward outsourcing specialist operations and care to cut costs and enhance healthcare results. For example, in Mexico, most dialysis treatments are supplied by private corporations that are under contract with governmental healthcare institutions. Additionally, an increase in collaborations with US healthcare providers was observed to provide cardiac care, cancer treatment, and other specialist care in Mexican institutions or for patients to fly to the US. As a result, hospitals may save money on plants and equipment, materials, medications, and tools, while still having access to some of the most cutting-edge specialty surgical treatments.
What are the key deal types in the Mexico pharmaceutical market?
The key deal types in the Mexico pharmaceutical market are strategic alliances, mergers & acquisitions, contract service agreements, and capital raisings. The most common deal type was strategic alliances, followed by mergers and acquisitions (M&A). This is in line with general deal-making trends in pharma, where there tend to be more partnerships and funding than M&As.
Mexico pharmaceutical market, by deal types
For more deal type insights, download a free report sample
Which are the key companies in the Mexico pharma market?
Some of the key companies in the Mexico pharma market are F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., Boehringer Ingelheim International GmbH, Genomma Lab Internacional SAB de CV, Teva Pharmaceutical Industries Ltd, Laboratorios Serral SA de CV (a subsidiary of Endo International Plc), and Laboratorios Silanes SA de CV.
Market Report Scope
Market size (Year – 2020)
|Key deal types||Strategic Alliances, Mergers & Acquisitions, Contract Service Agreement, and Capital Raisings|
|Key pharma companies||Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., Boehringer Ingelheim International GmbH, Genomma Lab Internacional SAB de CV, Teva Pharmaceutical Industries Ltd, Laboratorios Serral SA de CV (a subsidiary of Endo International Plc), and Laboratorios Silanes SA de CV.|
- This report provides an assessment of the major industry, regulatory, macroeconomic, and technology trends shaping the Mexico pharma industry.
- It provides a detailed analysis of deals, clinical trials, marketed and pipeline products, and contract manufacturing.
- It also provides an overview of key regulatory and market access information, market drivers and barriers, and key players in the Mexican pharma sector.
Reasons to Buy
- See what trends are shaping the Mexican pharma market and driving innovation, including key government policies and strategic initiatives.
- Get an analysis of Mexico’s strong manufacturing and outsourcing sector, including plans to further strengthen these capabilities.
Table of Contents
1.1.1. Table of Contents
1.1.3. Related Reports
1.2. Executive Summary
1.2.1. Key Findings
1.3.1. Mexico’s Pharma Market: Growing Capabilities but Poor Infrastructure
1.3.2. Key Influencer Twitter Chat Related to Mexico
1.4.1. Industry Trends – Large Pharma Companies Are Investing in Mexico
1.4.2. Industry Trends – Mexican Government Commitment to Healthcare Market Growth
1.4.3. Industry Trends – Increasing Manufacturing Potential in Mexico
1.4.4. Industry Trends – The Mexico Pharma Market is Dominated by Generics
1.4.5. Industry Trends – Low Levels of R&D Innovation
1.4.6. Industry Trends – Increasing Investment in Healthtech
1.4.7. Industry Trends – CNS and Infectious Disease Lead the Pharma Market
1.4.8. Industry Trends – Mexico has a Growing Medical Tourism Industry
1.4.9. Regulatory Trends – Regulatory Trends in Mexico
1.4.10. Regulatory Trends – Corruption and Infrastructure Barriers Limit Public Trust
1.5. Value Chain
1.6. Market Analysis
1.6.1. Mexico’s Pharma Market Will See Moderate Growth to 2025
1.6.2. Strategic Alliances Are the Leading Deal Type in Mexico
1.6.3. Licensing Agreements Lead Strategic Alliance Activity in Mexico
1.6.4. Examples of Licensing Agreements in Mexico 2018–2022YTD
1.6.5. Asset Transactions Lead With Majority of M&A Deals in Mexico
1.6.6. Minimal Capital Raising and CSA Activity in Mexico
1.6.7. Examples of Recent Health Technology Deals in Mexico
1.7. Clinical Trials
1.7.1. The Number of Clinical Trials in Mexico
1.7.2. The Majority of Trials in Mexico Are Mid/Late Phase
1.7.3. Infectious Disease Indications Dominate Clinical Trials in Mexico
1.7.4. Major Sponsors of Clinical Trials in Mexico
1.7.5. Top 10 Clinical Trials Sites in Mexico by Historical Volume
1.7.6. Top 10 Clinical Trial Investigators in Mexico by Historical Volume
1.7.7. Top 10 Trials in Mexico by Completed Enrollment Since 2019
1.8. Marketed Products
1.8.1. US Is the Largest Importer of Pharmaceuticals from Mexico
1.8.2. Generics Have the Largest Share of Marketed Drugs in Mexico
1.8.3. Majority of Marketed Drugs in Mexico Target CNS Disorders
1.8.4. Leading Drug Manufacturers in Mexico
1.8.5. The Majority of Marketed Biologics in Mexico Target Infectious Disease
1.8.6. Examples of Mexico-Approved Biologics (Innovator, Vaccines, etc.)
1.8.7. Currently Approved COVID-19 Vaccines in Mexico
1.8.8. Mexico in Top 10 Countries of COVID-19 Vaccinations Administered
1.9. Pipeline Products
1.9.1. Majority of Pipeline Drugs Are in Phase III and Most Are Innovator Biologics
1.9.2. Laboratorios Silanes Leads in Pipeline Products in Mexico
1.9.3. Infectious Disease Leads Pipeline Drug Development in Mexico
1.9.4. Most Innovator Biologics Are in the Infectious Disease Space
1.9.5. Pipeline COVID-19 Vaccines and Treatments in Mexico
1.9.6. Examples of Pipeline COVID-19 Vaccines and Other Treatments in Mexico
1.10. Contract Manufacturing in India
1.10.1. Contract Manufacturing Companies and Facilities in Mexico
1.10.2. CDMO Facilities Distribution in Mexico
1.11. Regulatory and Market Access
1.11.1. Overview of Healthcare System in Mexico
1.11.2. Organization of Healthcare System in Mexico
1.11.3. Drug Approval Process in Mexico
1.11.4. Regulation of Drugs in Mexico – Generics
1.11.5. Regulation of Drugs in Mexico – Biologics and Biosimilars
1.11.6. Market Access for Drugs in Mexico – Drug Pricing
1.11.7. Market Access for Drugs in Mexico – Reimbursement
1.11.8. Market Access for Drugs in Mexico – Regulatory Landscape
1.12. Market Drivers and Barriers
1.12.1. Market Drivers in Mexico
1.12.2. Market Barriers in Mexico
1.13.4. Boehringer Ingelheim
1.13.5. Genomma Lab
1.13.7. Laboratorios Serral SA de CV
1.13.8. Laboratorios Silanes SA de CV
1.14.2. Key Themes Impacting the Pharmaceutical Industry
1.14.3. Our Thematic Research Methodology
1.14.4. About the Authors
1.14.5. Contact Us
Frequently Asked Questions
Tel +44 (0) 20 7947 2960
Personal and transaction information are kept safe from unauthorised use.